TRDA News and Press, Entrada Therapeutics Inc. From 09/28/22

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nath...

Entrada Therapeutics press release ( NASDAQ: TRDA ): Q2 GAAP EPS of -$0.74 misses by $0.02 . Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021. For further details see: ...

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244 million in cash, cash equivalents and marketable securities as of June 30, 2022 ...

The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome measures and endpoints for clinical trials Entrada recently announced new preclinica...

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appoi...

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Gainers: USA Truck USAK +111%. ToughBuilt Industries TBLT +58%. Zendesk ZEN +29%. Femasys (FEMY) +30%. Chimerix CMRX +25%. Wrap Technologies (WRAP) +26%. Moving iMage Technologies MITQ +18%. TRACON Pharmaceuticals TCON +18%. LogicMark (LGMK) +16%. Zhong Yang Fina...

Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%.  Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...